Oppenheimer Sees Amgen Stock Price Reach New Heights
Amgen (NASDAQ:AMGN) stock has received a boost from Oppenheimer, which raised its price objective for the medical research company to $450.00, up from $400.00.
This represents a potential upside of 15.20% from Amgen's previous close.
The brokerage firm maintains an 'outperform' rating on the stock.